BLASINGLE-USEVIAL
Approved
Jun 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPOGEN/PROCRIT is a recombinant erythropoietin (EPO) cytokine indicated for anemia across chronic kidney disease, end-stage renal disease, chemotherapy-induced anemia, and multiple off-label uses including neuroprotection and wound healing. The drug stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. It has been a foundational biologic since 1989, with a mature indication portfolio spanning oncology, nephrology, and emerging neurology.
LOE Approaching
LOE approaching signals smaller commercial team, reduced promotional intensity, and shifting focus to retention and specialty segment defense rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage
Started Apr 2024
60 enrolled
Intraventricular Hemorrhage of Prematurity
Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis
Started Nov 2022
85,259 enrolled
Chronic Kidney Disease
Impact of Erythropoietin on Hematological Adaptations and Physical Performance
Started Sep 2021
8 enrolled
Exercise-Induced AnemiaPhysical Performance
A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)
Started Feb 2021
25 enrolled
Anemia of Chronic Kidney Disease
A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
Started Mar 2020
105 enrolled
Patient of Anemia in Chronic Renal Failure With Hemodialysis
Worked on EPOGEN/PROCRIT at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.